IL-15 treatment results in decreased lipid deposition in 3T3-L1 mature adipocytes and IL-6 and KC production with increasing IL-15 treatment. by Nicole G. Barra (317230)

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

A decreased response to yeast odorant attractant is observed in <i>sema1a</i> knockdown animals. by Keshava Mysore (413368)

HoxA9 represses and C/EBPα activates the <i>Cebpa</i> +8 kb enhancer in immature myeloid cells. by Lei Peng (260321)

Subjects:

Pan-JAK inhibitor P6 decreased ISG expression and increased susceptibility of BEAS-2B cells to H1N1 influenza virus infection. by Lai-Giea Seng (644370)

“…BEAS-2B cells were pre-treated with P6 at a final concentration of 2.5 or 5 µM for 24 h and infected with H1N1 influenza virus at 1.0 MOI (based on MDCK cells). …”

JTXK granule decreased the plasma insulin concentration, and improved insulin sensitivity in T2DM KKAy mice. by Na Yu (151735)

Overview regarding the used assays and observation time points. by Fabian Westhauser (5314436)

Hsp72 overexpression decreases total NF-κB-p65 in resting cells and reduces steady state IκBα protein levels. by Patrick W. Sheppard (586664)

“…Gray data points are rescaled from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003471#pcbi-1003471-g001" target="_blank">Fig. 1B</a>. …”

Mean red and green fluorescence intensity data from three experiments of cyanobacteria. by Emma T. Brentjens (17295999)

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Subjects:

Zebrafish PGRP5 exhibits differential expression characteristics under different bacterial stimuli. by Xi Li (19208)

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Subjects:

Data extraction grid. by Heloisa Ricci Conesa (18291210)

Subjects:

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

Subjects:

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

Subjects:

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

Subjects:

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)

Subjects:

A summary of calibration standards (n = 3). by Ewa Paszkowska (21246702)

Subjects:

Outcome measures on step 5. by Timmion K. Skervin (11432568)